- Home
- HOWL vs NRXP Comparison
HOWL vs NRXP Comparison
Compare HOWL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- NRXP
- Stock Information
- Founded
- HOWL 2017
- NRXP 2015
- Country
- HOWL United States
- NRXP United States
- Employees
- HOWL N/A
- NRXP N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- NRXP Health Care
- Exchange
- HOWL Nasdaq
- NRXP Nasdaq
- Market Cap
- HOWL 64.5M
- NRXP 58.5M
- IPO Year
- HOWL 2021
- NRXP N/A
- Fundamental
- Price
- HOWL $1.56
- NRXP $3.05
- Analyst Decision
- HOWL Strong Buy
- NRXP Strong Buy
- Analyst Count
- HOWL 5
- NRXP 5
- Target Price
- HOWL $7.20
- NRXP $31.40
- AVG Volume (30 Days)
- HOWL 1.3M
- NRXP 429.4K
- Earning Date
- HOWL 11-14-2025
- NRXP 11-13-2025
- Dividend Yield
- HOWL N/A
- NRXP N/A
- EPS Growth
- HOWL N/A
- NRXP N/A
- EPS
- HOWL N/A
- NRXP N/A
- Revenue
- HOWL N/A
- NRXP N/A
- Revenue This Year
- HOWL N/A
- NRXP N/A
- Revenue Next Year
- HOWL N/A
- NRXP $395.09
- P/E Ratio
- HOWL N/A
- NRXP N/A
- Revenue Growth
- HOWL N/A
- NRXP N/A
- 52 Week Low
- HOWL $0.60
- NRXP $1.12
- 52 Week High
- HOWL $2.96
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- HOWL 45.71
- NRXP 46.72
- Support Level
- HOWL $1.55
- NRXP $3.05
- Resistance Level
- HOWL $1.83
- NRXP $3.32
- Average True Range (ATR)
- HOWL 0.13
- NRXP 0.22
- MACD
- HOWL -0.03
- NRXP -0.04
- Stochastic Oscillator
- HOWL 14.71
- NRXP 20.59
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.